429 related articles for article (PubMed ID: 29574225)
1. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
2. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
3. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK.
Huang Q; Wang T; Yang L; Wang HY
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534819
[TBL] [Abstract][Full Text] [Related]
4. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
5. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
[TBL] [Abstract][Full Text] [Related]
6. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
Zhang J; Du H; Shen M; Zhao Z; Ye X
J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
[TBL] [Abstract][Full Text] [Related]
7. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease
Li CX; Gao JG; Wan XY; Chen Y; Xu CF; Feng ZM; Zeng H; Lin YM; Ma H; Xu P; Yu CH; Li YM
World J Gastroenterol; 2019 Sep; 25(34):5120-5133. PubMed ID: 31558861
[TBL] [Abstract][Full Text] [Related]
8. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation.
Pyun DH; Kim TJ; Park SY; Lee HJ; Abd El-Aty AM; Jeong JH; Jung TW
Mol Cell Endocrinol; 2021 Dec; 538():111464. PubMed ID: 34601002
[TBL] [Abstract][Full Text] [Related]
9. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
[TBL] [Abstract][Full Text] [Related]
10. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
Yin X; Liu Z; Wang J
Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
[TBL] [Abstract][Full Text] [Related]
11. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
Liu Y; Li Y; Wang J; Yang L; Yu X; Huang P; Song H; Zheng P
BMC Complement Med Ther; 2022 Aug; 22(1):213. PubMed ID: 35945571
[TBL] [Abstract][Full Text] [Related]
12. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
Li Y; Liu Y; Chen Z; Tang K; Yang L; Jiang Y; Wang J; Huang P; Wang J; Zheng P; Song H
Biomed Pharmacother; 2023 Apr; 160():114319. PubMed ID: 36724639
[TBL] [Abstract][Full Text] [Related]
13. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
14. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
Xu N; Luo H; Li M; Wu J; Wu X; Chen L; Gan Y; Guan F; Li M; Su Z; Chen J; Liu Y
Biomed Pharmacother; 2021 Feb; 134():111104. PubMed ID: 33341045
[TBL] [Abstract][Full Text] [Related]
15. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
[TBL] [Abstract][Full Text] [Related]
16. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
[TBL] [Abstract][Full Text] [Related]
17. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.
Li N; Yin L; Shang J; Liang M; Liu Z; Yang H; Qiang G; Du G; Yang X
Biomed Pharmacother; 2023 Sep; 165():115113. PubMed ID: 37418974
[TBL] [Abstract][Full Text] [Related]
18. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
[No Abstract] [Full Text] [Related]
19. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet.
Liou CJ; Lee YK; Ting NC; Chen YL; Shen SC; Wu SJ; Huang WC
Cells; 2019 May; 8(5):. PubMed ID: 31083505
[TBL] [Abstract][Full Text] [Related]
20. γ-Mangostin Ameliorates Free Fatty Acid-Induced Lipid Accumulation via the SIRT1/LKB1/AMPK Pathway in HepG2 and L02 Cells.
Gu L; Cai N; Lyu Y; Yao L; Wang F; Xu H; Hu Z; Li H; Xu X
J Agric Food Chem; 2019 Dec; 67(50):13929-13938. PubMed ID: 31674780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
